Pfizer Inc. (NYSE:PFE) Holdings Trimmed by Corrado Advisors LLC

Corrado Advisors LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 13.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,708 shares of the biopharmaceutical company’s stock after selling 9,515 shares during the quarter. Corrado Advisors LLC’s holdings in Pfizer were worth $1,777,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of PFE. Briaud Financial Planning Inc bought a new position in Pfizer during the third quarter valued at about $30,000. GoalVest Advisory LLC boosted its stake in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. bought a new position in Pfizer during the third quarter valued at about $34,000. VisionPoint Advisory Group LLC boosted its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new stake in shares of Pfizer during the fourth quarter valued at $36,000. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on PFE shares. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday, April 15th. Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Stock Up 0.2 %

Shares of NYSE PFE traded up $0.06 during mid-day trading on Tuesday, reaching $26.32. 24,286,365 shares of the company traded hands, compared to its average volume of 42,105,117. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a market cap of $149.04 billion, a PE ratio of 73.11, a price-to-earnings-growth ratio of 1.17 and a beta of 0.61. The company’s fifty day moving average is $27.08 and its two-hundred day moving average is $28.56. Pfizer Inc. has a fifty-two week low of $25.23 and a fifty-two week high of $40.37.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.14 EPS. On average, analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.